Aspire Biopharma Holdings Inc's Business Segments

Aspire is a biopharmaceutical company incorporated in Delaware in February 2025, specializing in sublingual delivery technologies for existing drugs, with an initial focus on aspirin. Its proprietary, patent-pending sublingual delivery system facilitates rapid drug absorption into the bloodstream by bypassing the gastrointestinal tract, enabling faster therapeutic effects and high-dose absorption. Aspire's lead product candidate is a high-dose sublingual aspirin formulation aimed at providing faster bioavailability and reduced gastrointestinal toxicity compared to standard oral aspirin. A clinical trial completed in July 2025 demonstrated these benefits, supporting a planned FDA 505(b)(2) New Drug Application submission in late 2026. The company contracts third-party manufacturers, including Glatt and Microsize, for production and packaging and does not own manufacturing facilities. Aspire intends to commercialize its aspirin products primarily in the United States, potentially through a targeted hospital and specialty care sales force or licensing agreements, and plans to establish marketing, sales, and Medical Affairs teams to support commercialization. The company's technology also has applications for other drugs and nutraceuticals delivered as soluble, fast-acting powders or granules, with additional patent applications filed to protect these innovations.

The Company has identified a single reportable segment. The Chief Executive Officer, serving as the chief operating decision-maker (CODM), evaluates the Company's overall assets, operating results, and financial metrics to allocate resources and assess financial performance. Performance assessment focuses on operating expenses reported as net income and total assets as presented in the consolidated balance sheet. Key metrics reviewed include operating expenses—comprising general and administrative, research and development, and sales and marketing costs—as well as cash and cash equivalents. These metrics are monitored to manage and forecast cash flow, ensure adequate capital for operations, and maintain compliance with contractual obligations. The operating expense categories reported in the statements of operations represent the primary segment expenses regularly reviewed by the CODM.